The involvement of metabolites of arachidonic acid in platelet-dense granule secretion and secondary platelet-platelet interactions is well characterized. However, their role in heterotypic interactions dependent on a-granule secretion is less well understood. Using platelet-surface expression of P-selectin as a marker of a-granule secretion, we have shown that: (1) aspirin treatment of platelets at doses that block dense granule secretion does not inhibit a-granule secretion to adenosine diphosphate (ADP); (2) synergism between epinephrine and ADP in the induction of P-selectin expression is similarly unaffected by aspirin; and (3) the ability of P-selectin to mediate adhesion of activated platelets to monocytes and polymorphonuclear lymphocytes in whole blood is also unchanged by aspirin treatment. To LATELET a-GRANULE release is an aspect of plate-P let activation that occurs more readily than dense granule secretion in response to weak agonists, but the mechanisms leading to membrane fusion and secretion ofthe two granule types have generally been assumed to be similar. Dense granule secretion is required for homotypic (plateletplatelet) interactions, whereas a-granules appear to be central to platelet trafficking with other cell types (heterotypic interactions). P-selectin, expressed after fusion of the agranule with the platelet surface membrane, mediates activated platelet-leukocyte adhesion. In addition, there is growing interest in the role of a-granule contents (eg, transforming growth factor+ [TGF-PI and platelet-derived growth factor [PDGF]'") in the modulation of vascular injury and repair mechanisms. In particular, the failure of aspirin and other cyclooxygenase inhibitors to prevent restenosis of atherosclerotic lesions after angiop1asty4s5 and the emerging importance of aspirin-independent thromboregulation6*' raises questions regarding the dependency of agranule release on products of arachidonate metabolism. We have studied the effects of inhibition of platelet cyclooxygenase, lipoxygenase, and Na+/H+ exchange on the secretion of platelet a-granules in response to adenosine diphosphate (ADP), using the detection of P-selectin-positive platelets as an index of a-granule release and the binding of leukocytes and P-selectin-positive platelets as a marker for P-selectin function.
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purified whole IgG,. The MoAb 1E3' (donated by Dr K. Auk, Maine Medical Center Research Institute, South Portland, ME) is specific for P-selectin (GMP-140/PADGEM, CD62). P29 (AMAC, Westbrook, ME) recognizes glycoprotein IIb/IIIa (GPIIb/IIIa). Anti-CD45 (HLE; Becton-Dickinson Immunocytometry Systems, San Jose, CA) recognizes a CD45 isoform present on neutrophils, monocytes, and lymphocytes, but not erythroid cells or platelets.
Aggregometry. Whole blood from normal volunteers on no medications was drawn into sodium citrate at 0.38% final concentration. Platelet-rich plasma (PRP) and platelet-free plasma were prepared in the standard fashion, and the platelet count in the PRP was adjusted to 2.5 X 10'/mL. Standard platelet aggregometry was performed at 37°C using a dual sample DP-247E aggregometer (Sienco, Momson, CO). To determine that agonists were active, PRP samples were stimulated with agonists to show complete platelet aggregation. For in vitro ASA inhibition experiments, PRP was incubated with ASA (500 pmol/L to 5 mmol/L)'' or diluent at 37°C for 60 minutes (unless otherwise indicated) before the addition of agonist. The adequacy of aspirin-treatment at the above doses and continued function of the diluent-treated PRP was ensured by awegometry of both PRP samples with arachidonic acid at a final concentration of 0.5 and 1 mg/mL. These arachidonic acid experiments showed normal primary and secondary aggregation in the diluent-treated PRP and complete inhibition of aggregation in the aspirin-treated sample.
To further confirm inhibition of platelet-dense granule release by in vitro incubation with ASA, endogenous platelet serotonin content was measured in samples of PRP after awegometry as previ-506 RINDER ET AL ously described." In brief, PRP incubated with ASA (500 pmol/L final concentration) or diluent was examined with aggregometry as above using as agonist 5 pmol/L ADP. The entire contents of the aggregometry tube were aspirated onto a filter, and the filter was examined for serotonin content by high performance liquid chromatography (HPLC). All samples were incubated with 10 pmol/L fluoxetine to block reuptake of serotonin. Comparison of serotonin content in equal volumes of aspirin-and diluent-treated unaggregated PRP yielded the percentage of serotonin release. Each experiment was performed four times.
In preliminary experiments to determine the optimal time course of ADP stimulation, fresh untreated PRP was mixed with agonist or diluent by brief (1 second) vortexing and incubated at 37°C at time 0. Timed samples were then removed at 5, IO, and 15 minutes and immediately added to paraformaldehyde ( I% final concentration); these samples were fixed for 60 minutes at 4°C before washing and labeling with antibody to determine P-selectin expression, as previously described. " 4 ' To examine P-selectin expression after a variable duration of ASA incubation, PRP was treated with ASA (500 pmol/L final) or diluent at time 0 and placed at 37°C. At 15, 30, and 60 minutes, samples were removed for baseline levels of P-selectin and for stimulation with 3 doses of ADP to determine agonist-induced P-selectin expression. All other in vitro ASA experiments used PRP incubated with ASA or diluent for 60 minutes at 37°C before the addition of other inhibitors or agonists.
To determine if platelet lipoxygenase has a significant role in P-selectin expression, ET1 (5 to 20 pmol/L) or control diluent was incubated with fresh PRP for 15 minutes at 37°C before the addition of ADP in separate experiments, PRP from donors who had ingested ASA (see below) were incubated with ET1 or diluent before ADP stimulation to determine if overproduction of 12-Hydroxyeicosatetraenoic acid ( 12-HETE) in cyclooxygenase-inhibited platelets had an effect on P-selectin expression. For examination of the role of Na+/H+ exchange in ADP-induced P-selectin expression, fresh PRP (no ASA treatment) was incubated with amiloride or HCl (the latter titrated the PRP to a pH of 6.8) before agonist. Samples were fixed after agonist and then washed into normal pH buffer before antibody labeling. Amiloride activity and pH effect were confirmed by inhibition of aggregometry of fresh PRP to ADP.
For thrombin stimulation experiments, PRP was gel-filtered using Sepharose 2B (Pharmacia, Piscataway, NJ) as previously described.16 Gel-filtered platelets were adjusted to a count of 1.5 X 108/mL, incubated with 500 pmol/L ASA or diluent for 60 minutes at 37"C, and then stimulated with 0.01 U/mL thrombin for 5 minutes at 37°C. Samples were then fixed in I% (final) paraformaldehyde as above, washed, and examined for P-selectin expression.
0-Thromboglobulin (PTG) measurements in PRP.
The percentage of /3TG release was measured as previously described." In brief, PRP incubated for 60 minutes with ASA or diluent was stimulated with 5 pmol/L ADP as above. Timed samples were then fixed for P-selectin expression or drawn immediately into cold stabilizing buffer and subsequently centrifuged for platelet-free supernatant to determine PTG in the releasate.18 Identical volumes of PRP were completely lysed with Triton X-100 (Sigma) to determine total PTG content. Released /3TG was then expressed as a percentage of total content. Each experiment was performed in duplicate.
Leukocyte-platelet adhesion in whole blood. Citrated whole Mood was incubated with 500 pmol/L ASA or diluent for 60 minutes at 37°C. Whole-blood samples were then stimulated with epinephrine (1 pmol/L) for 10 minutes at 3 7 T , followed by ADP (5 pmol/L) at 37°C as previously de~cribed;'~ timed whole-blood samPlatelet P-selectin expression in PRP.
ples were then removed directly into 1% paraformaldehyde. Samples were fixed for 60 minutes, washed, and examined for platelet P-selectin expression and the percentage of leukocyte-platelet conjugates.
In vivo aspirin treatment. Experiments in which whole blood or PRP were incubated with aspirin in vitro were confirmed in identical experiments using blood obtained from volunteers before aspirin ingestion and after two doses of 650 mg of aspirin (aspirin taken 8 hours and 1 hour before phlebotomy). PRP was made from the sample obtained before aspirin ingestion and immediately tested by aggregometry to confirm complete aggregation to all agonists, including arachidonic acid (0.5 and 1.0 mg/mL); the PRP sample obtained after two doses of aspirin was similarly tested by aggregometry and showed complete absence of aggregation to arachidonic acid and absent second wave to ADP. Both PRP samples (albeit on separate days) were then subjected to stimulation by ADP, as well as ETI/diluent incubation before ADP. Whole-blood samples at the same time points were stimulated with epinephrine/ ADP.
Flow cytometry.
In both PRP and whole-blood experiments, the determination of the percentage of platelets expressing P-selectin (P-selectin-positive platelets) and the mean fluorescence of platelet P-selectin was performed as previously described, using biotin-1E3 and phycoerythrin-~treptavidin.~~~'~~'~~~~ In brief, leukocytes were excluded with a combination of size and platelet-specific marker (anti-GPIIb/IIIa) gating. A threshold for P-selectin positivity was set usingan irrelevant isotype-specific MoAb. Mean P-selectin fluorescence for the entire platelet population was expressed in arbitrary fluorescence units. The determination ofthe percentage of neutrophil-platelet and monocyte-platelet conjugates in whole blood after epinephrine/ADP was performed as previously descril~ed.'~.~' In brief, neutrophils and monocytes were acquired using a combination of size and the specific leukocyte marker anti-CD45, thus excluding unbound platelets. Using size and right-angle scatter, the neutrophils and monocytes were analyzed separately for platelet-marker (GPIIb/IIIa) fluorescence (again using a threshold set with an irrelevant isotype-specific MoAb). Leukocytes with positive platelet marker fluorescence were expressed as the percentage of leukocyte-platelet conjugates (relative to the total number of leukocytes).
RESULTS
Platelet aggregometry and serotonin release. In vitro incubation of PRP with 500 pmol/L aspirin for 60 minutes consistently resulted in complete inhibition of platelet aggregation to arachidonic acid at 0.5 and 1.0 mg/mL final concentration; by contrast, the diluent-treated (ETOH) PRP showed normal primary and secondary wave aggregation to the same arachidonic acid doses, thus serving as a positive control. Incubation of PRP with 500 pmol/L aspirin for 60 minutes consistently produced complete inhibition of second-wave aggregation in response to 2 to 10 pmol/L ADP (Fig IA) , compared with diluent-treated P R P at the same dose of ADP (Fig 1 B) . As expected, the primary wave of ADP-induced aggregation was unaffected by aspirin treatment. The only effect of increasing doses of A D P o n aspirin-treated PRP was to prolong the disaggregation phase of the primary wave.
To confirm that inhibition of ADP-induced second-wave aggregation by aspirin correlated with inhibition of dense granule release, platelet aggregation was combined with measurement of platelet serotonin content as detailed in Materials and Methods. Total platelet serotonin content preagonist was 4 1 .O f 2.1 ng/mL. Stimulation of diluenttreated PRP with 5 pmol/L ADP (Fig IB) resulted in second-wave aggregation and 55.4% k 9.8% serotonin release (22.7 f 3.8 ng/mL); aspirin-treated PRP showed no second wave to 5 pmol/L ADP (Fig 1 A) , and serotonin release was only 3.2% f 3.6% (1.2 f 0.9 ng/mL). As noted in Materials and Methods, the serotonin release assay was performed in the presence of fluoxetine. Preliminary experiments were performed to identify the time course of peak P-selectin expression in response to ADP; the percentage of P-selectin-positive platelets was found to plateau at 5 minutes after addition of agonist. The percentage of P-selectinpositive platelets in response to 5 pmol/L ADP (expressed as a percentage of the 5-minute value) at 10 and 15 minutes after ADP were 98% f 9% and 96% & lo%, respectively (mean & SD for 5 experiments). The mean P-selectin fluorescence similarly peaked at 5 minutes. Platelet P-selectin response to 2 pmol/L and 10 pmol/L ADP likewise peaked at the 5-minute time point. Therefore, P-selectin expression in all ADP agonist experiments was subsequently measured 5 minutes after the addition of ADP. Table 1 examines P-selectin expression during time of aspirin incubation. PRP was incubated with aspirin or diluent for 15, 30, and 60 minutes; aliquots were stimulated with 2, 5, and 10 pmol/L ADP for 5 minutes. As shown in Table 1 , incubation with aspirin for up to 60 minutes resulted in no inhibition of the ADP-induced increase in P-selectin-positive platelets when compared with ADP stimulation of diluent-treated controls ( P > .05 by paired t-test).
Platelet expression of P-selectin.
The mean P-selectin expression per platelet also did not show inhibition by aspirin treatment. The baseline percentage of platelets expressing P-selectin in the PRP before addition of ASA or diluent was 3.8% f 1.3% with a mean P-selectin fluorescence of 4.1 t 2.6. After 60 minutes of incubation in ASA, the baseline percentage of P-selectinpositive platelets and the mean P-selectin fluorescence were 5.6% f 2.3% and 3.3 k 2.2, respectively, while the diluenttreated sample had a baseline value of 5.4% ? 1.7% and 3.5 +-2.3, respectively (mean k SD for 5 experiments). Thus, incubation with ASA or diluent did not produce artifactual platelet activation to a degree that might obscure aspirin inhibition of P-selectin release to agonist. Figure 2 shows representative contour graphs of PRP incubated with aspirin or diluent, then stimulated with buffer, ADP 5 pmol/L, or thrombin 0.0 1 U/mL. Aspirin treatment did not inhibit the increase in the percentage of P-selectin-positive platelets to ADP and thrombin, nor did aspirin affect the mean P-selectin fluorescence per platelet after agonist addition.
The increase in P-selectin after addition of ADP was accompanied by formation of a small number of microaggregates. The percentage of platelets in microaggregate form and the size of the microaggregates did not differ between the aspirin-treated and control samples. The uniformity of platelet "size" and percentage of microaggregates formed in the aspirin-treated and control samples ensures that greater a-granule release in the control sample was not masked by aggregation of the activated platelets. This was confirmed by analyzing platelet P-selectin using single-platelet forwardscatter gates: with this single-platelet gate, there was no difference in the percentage of P-selectin-positive platelets or the mean P-selectin fluorescence between control and aspirin-treated samples. In addition, to determine whether a-granule release had a higher threshold for inhibition than dense granule release, the in vitro dose of aspirin was increased as high as 5 mmol/L; no inhibition of P-selectin induction on ADP-stimulated platelets was noted. Similar results were obtained after volunteer subjects took 650 mg of aspirin 8 hours and 1 hour before phlebotomy. Secondwave aggregometry was completely inhibited to 2 to 10 pmol/L ADP, whereas ADP-induced platelet P-selectin expression in PRP was unaffected compared with samples drawn before aspirin ingestion (data not shown). As noted in Materials and Methods, adequate aspirin treatment was confirmed by arachidonic acid aggregometry before and after aspirin ingestion.
To further confirm lack of inhibition of a-granule release by ASA, PTG release was measured as a percentage of total platelet content of PTG. Samples were assayed 5 and IO minutes after ADP (5 pmol/ L final); PTG release at these time points in the aspirintreated sample were 98% f 17% and 110% * 29% of the diluent-treated sample, respectively.
We confirmed a previous finding that preincubation of PRP with 1 pmol/L epinephrine causes an enhanced aggregation response to low doses of ADP. In unstirred PRP, addition of 1 pmol/L epinephrine does not produce a significant increase in P-selectin expresExamination ofPTG release.
Platelet agonist synergy.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From All values are the mean (SD) of five experiments. Duration of incubation with ASA, 500 pmol/L or diluent, followed by 5 minutes of ADP stimulation sion compared with no agonist, suggesting that platelet-platelet contact is important for epinephrine-induced a-granule release (Fig 3) . However, preincubation of PRP with 1 pmol/L epinephrine followed by 2 pmol/L or 5 pmol/L ADP produced a synergistic increase in P-selectin expression: a 98% * 18% increase over the sum of the single ago- For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From Efect of Na+/H+ transport on a-granule release. Na+/ H+ exchange has been shown to be effectively blocked by increasing the extraplatelet [H+].2',22 Acidification of PRP to a pH of 6.8 resulted in a 43% t-5% inhibition (mean k SD for four experiments) of P-selectin expression in response to 5 pmol/L ADP. Inhibition of Na+/H+ exchange with amiloride at doses of 0.05 mmol/L, 0.1 mmol/L, 0.5 mmol/L, and 1 mmol/L also inhibited platelet expression of P-selectin in response to 5 pmol/L and 10 pmol/L ADP in a doseresponse fashion (Fig 4) . Inhibition appeared to be maximal at 0.5 mmol/L amiloride. Platelet aggregation in response to 5 pmol/L ADP was completely inhibited at a pH of 6.8, and amiloride-treated PRP also showed dose-dependent inhibition of ADP-induced aggregation in the same dose range of amiloride that inhibited ADP-induced P-selectin expression.
Aspirin efect on P-selectin function. We have previously shown that stimulation of whole blood with epinephrine followed by ADP results in increased monocyte-platelet and polymorphonuclear leukocytes (PMN)-platelet adhesion that is P-selectin de~endent.'~ As shown in Table 2 , aspirin incubation of whole blood followed by stimulation with epinephrine/ADP did not inhibit either P-selectin expression on unbound platelets, nor the increase in the percentage of monocytes binding platelets. The small increase in PMNplatelet binding after ADP stimulation, which is quantitatively lower in whole blood compared with monocyte-platelet binding, also was not inhibited by aspirin (data not shown).
DISCUSSION
Cellular homeostasis in the blood includes both homotypic (platelet-platelet) and heterotypic cell-platelet interactions. The ability of aspirin to inhibit platelet homotypic adhesion in response to weak agonists such as ADP has been well established. Platelet-heterotypic cell interactions have been examined for their role in the regulation of thrombosis, inflammation, and vasomotor t~ne.~,',*~-~' The a-granule is critical to a number ofthese heterotypic reactions. The a-granule contains platelet-derived growth factor and TGF-/ 3, which have their primary effects on cells other than platelets. In addition, P-selectin, which is present on the internal membrane of the a-granule in the resting platelet,26,27 is expressed on the platelet surface after agonist-induced a-granule release. P-selectin belongs to the selectin family of adhesion molecules and mediates the binding of activated platelets to monocytes and PMN.28"0 In the present study, we examined the ability of aspirin to inhibit antigenic and functional platelet P-selectin expression after stimulation by ADP.
The adequacy of aspirin treatment was assessed by routine aggregometry, where incubation of PRP for 60 minutes with 500 pmol/L aspirin completely inhibited aggregation to 0.5 and 1 mg/mL arachidonic acid, as well as secondwave aggregation in response to 2 to 10 pmol/L ADP. In addition, serotonin release was found to be completely inhibited in ADP-stimulated platelets that had been incubated with aspirin. By contrast, the increase in P-selectin expression in response to ADP, both in the percentage of P-selectin-positive platelets and the mean P-selectin fluorescence was unchanged by in vitro or in vivo aspirin treatment. The low background P-selectin expression in unstimulated platelets after aspirin/diluent incubation ensured that baseline activation did not obscure any potential aspirin inhibition of P-selectin expression. Increasing the dose of aspirin to pharmacologic levels ( 5 mmol/L) did not uncover a greater threshold for inhibition of a-granule release. The synergy between epinephrine and ADP that has been described for aggreg~metry~~ was also found to be true for a-granule release. The percentage of P-selectin-positive platelets in response to low-dose ADP was doubled by preincubation of the platelets with a dose of epinephrine that by itself produced insignificant a-granule release. This synergy with epinephrine may be caused by an increase in the avidity of the ADP receptor for its ligand.32 Aspirin treatment did not inhibit the synergistic increase in a-granule release induced by epinephrine pretreatment.
Aspirin treatment of platelets also did not affect the levels of PTG released in response to ADP. Thus, secretion of a-granule contents, as well as surface markers of a-granule release, were found to be unchanged by aspirin incubation. As a technique for detection of a-granule release, f l G levels in our laboratory have proven to be a less sensitive marker than P-selectin expression, in part because ofincreased sensitivity of flow cytometric techniques for low numbers of activated platelets.18 Nonetheless, our finding confirms the ability of platelets to release a-granule contents despite inhibition of cyclooxygenase. The trend toward a higher percentage of P-selectin-positive platelets in the aspirintreated samples suggested that excess production of a lipoxygenase product, such as 12-HETE, might promote a-granule release, overcoming any inhibitory effect of aspirin. However, experiments using the lipoxygenase inhibitor ET133,34 failed to show any inhibition of P-selectin expression when used alone or in combination with aspirin, making this explanation unlikely.
To determine whether the function of P-selectin as an adhesion molecule was preserved in aspirin-treated platelets, we measured platelet-leukocyte adhesion in aspirintreated whole blood. Our previous work has shown that stimulation of normal whole blood with 1 rmol/L epinephrine followed by 5 pmol/L ADP results in platelet activation and activated platelet adhesion to monocytes and PMN via P -~l e c t i n . '~ Both in vivo and in vitro aspirin treatment did not change either the percentage of P-selectin-positive platelets in epinephrine/ADP-stimulated whole blood, nor the adhesion of these activated platelets to monocytes or PMN. Metabolic cooperation between activated platelets and PMN has previously been described for the production of such vasoactive compounds as leukotnene B, and C,, dihydroxyeicosatetraenoic acid (DiHete),23,24 and Lipoxin A4 and B, .25 These leukocyte-platelet interactions similarly are not inhibitable by aspirin or indomethacin, and in vivo work suggests that their formation may even be enhanced by cyclooxygenase inhibiti~n.~' The role of platelet-leukocyte adhesion via P-selectin in this cooperativity is not known but might serve to maintain these cells in close proximity under conditions of high-shear stress. Na+/H+ exchange is an early event in platelet activation that appears to be particularly important in platelet stimulation by weak agonists such as ADP or low doses of thrombin.2' Inhibition of Na+/H+ transport has been shown to be critical to activation of phospholipase A, ,36 to the liberation of arachidonic acid," to regulation of the phosphoinositide cycle,37 and to transformation of GPIIb/IIIa to a form competent for fibrinogen binding.38 Blockade of Na+/H+ exchange by extracellular acidification has previously been found to be effective in inhibiting activation of phospholipase C and phospholipase A2 by ADP.22,36 We found that extracellular acidification to a pH of 6.8 similarly inhibited P-selectin expression by 43% in response to ADP stimulaFor personal use only. on November 11, 2017 . by guest www.bloodjournal.org From tion. Likewise, Na+/Hf transport can be inhibited by the diuretic amiloride, and this inhibition prevents platelet aggregation to ADP in a dose-dependent manner.39 Amiloride incubation of PRP similarly resulted in dose-dependent inhibition of P-selectin expression in response to ADP. The effects of extracellular acidification on platelet a-granule release may be important for the function of stored platelets for transfusion because there is growing evidence that P-selectin-positive platelets have a lower recovery after transfusion compared with unactivated platelets.'"' ADP-induced a-granule secretion and P-selectin expression in unstirred PRP proceed independently of arachidonic acid metabolites of both the lipoxygenase and cyclooxygenase pathways. However, a-granule secretion in response to ADP appears to require maintenance of the intracellular p H by the Na+/H+ transporter. Therefore, release of growth factors from the a-granule such as TGF-P and PDGF may be unaffected by cyclooxygenase inhibitors that block platelet-platelet interactions. In addition, as we have shown in this study, leukocyte-platelet interactions mediated by P-selectin are also independent of the metabolites of arachidonic acid. As the regulation of this pathway is further elucidated, it may prove possible to selectively inhibit a-granule secretion while preserving platelet aggregation.
